New leadership after a flat half

Surgical Innovations Group (LSE:SUN) has a new chief executive. In an announcement on 28 September 2026, the Leeds-based medical device maker said Alex Warnock would join the board as CEO from 1 October. David Marsh, who has spent nine years in executive roles at the company, becomes a non-executive director and will continue to support relationships and business development. Two days after that announcement, the group reported first-half revenue that was essentially flat.

What the company does

Surgical Innovations designs and manufactures devices for minimally invasive surgery, including port access systems, instruments and retraction devices. Many of its products use a partly reusable "Resposable" concept, which aims to cut cost and waste. It also makes devices for OEM partners. Through its subsidiary Elemental Healthcare, it distributes specialist third-party products in the UK.

Latest developments

Mr Warnock has more than 25 years of senior operational experience in high-tech manufacturing, photonics and regulated medtech. His previous roles include Group Managing Director of SDI Group and chief operating officer posts at Foster & Freeman, Gooch & Housego and Optos. Earlier in the year, on 15 June, the company appointed David Anderson as a fractional chief financial officer. Roy Davis now chairs the board. On 7 July, Elemental announced that it had secured a place on the MIS3 framework.

Financial picture

Revenue for the six months to 30 June 2026 was £6.02 million, against £6.15 million a year earlier. The company made a pre-tax loss of £248,000, compared with a small profit in the first half of 2025, and adjusted EBITDA fell to £33,000 from £373,000. Gross margin was 29.0%, down from 31.2%. Cash at bank was £361,000 and adjusted net debt was £309,000. The group repaid its remaining CBILS debt in full. Invoice financing headroom was about £0.2 million. In its full-year statement earlier in the year, the company had said it was targeting margin improvements through cost-reduction programmes, so the half-year decline in gross margin will be watched closely.

For the full year 2025, reported in April, revenue was £11.6 million and the statutory loss narrowed to £0.9 million. Sales of SI Branded products fell, which the company attributed largely to US tariffs. Europe and UK distribution both grew. No dividend is paid.

Sector and index context

Surgical Innovations is a small company measured against the FTSE AIM All Share Index, the benchmark for London's junior market. UK-listed medtech companies of this size have faced cost inflation, tariff disruption and long hospital procurement cycles, while scale and new product approvals often shape sentiment.

Key risks

The company has flagged customer concentration, regulatory approvals, supply-chain pressure and continuing US tariff headwinds as risks. Its balance sheet headroom is limited, with invoice financing headroom of about £0.2 million at the half-year. Leadership changes can also bring a period of transition.

What to watch next

Management expects a return to growth in the second half of 2026, led by Europe, the UK and Japan, with new product launches planned for the fourth quarter. The company is also exploring other routes to market in the United States. Shareholders will watch for early signals from Mr Warnock on strategy and for any further update on the board review of shareholder value that the company flagged in April, and on how quickly the new Logi-range products reach customers after MDR certification. The outlook for the OEM business under its new contract will also matter.